 | • レポートコード：MRC2302E0071 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、246ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社では、2021年に4,373.91百万ドルであった世界の細胞株開発市場規模が、2022年に4,986.69百万ドルに達し、2027年には年平均成長率14.19%で9,698.15百万ドルまで成長すると予測しています。当調査レポートでは、細胞株開発の世界市場の現状について調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、競争状況などの構成でまとめております。セグメント分析では、種類別（連続細胞株、ハイブリドーマ、初代細胞株、組換え細胞株）、ソース別（両生類、昆虫、哺乳類）、製品別（装置、培地＆試薬、その他）、用途別（生物生産、創薬、研究、組織工学＆再生医療、毒性試験）、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）の情報が含まれています。なお、当市場の主要企業には、AGC Biologics、Aragen Bioscience, Inc.、Boehringer Ingelheim International GmbH、Catalent, Inc.、Corning Incorporated、EuBiologics Co.,Ltd.、GE Healthcare、Genscript Biotech、Lonza Group AG、Merck KGaA、Rentschler Biopharma SE、Samsung Biologics Co., Ltd.、Sartorius AG、Selexis SAなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の細胞株開発市場規模：種類別 - 連続細胞株の市場規模 - ハイブリドーマの市場規模 - 初代細胞株の市場規模 - 組換え細胞株の市場規模 ・世界の細胞株開発市場規模：ソース別 - 両生類の市場規模 - 昆虫の市場規模 - 哺乳類の市場規模 ・世界の細胞株開発市場規模：製品別 - 装置の市場規模 - 培地＆試薬の市場規模 - その他製品の市場規模 ・世界の細胞株開発市場規模：用途別 - 生物生産における市場規模 - 創薬における市場規模 - 研究における市場規模 - 組織工学＆再生医療における市場規模 - 毒性試験における市場規模 ・世界の細胞株開発市場規模：地域別 - 南北アメリカの細胞株開発市場規模 アメリカの細胞株開発市場規模 カナダの細胞株開発市場規模 ブラジルの細胞株開発市場規模 … - アジア太平洋の細胞株開発市場規模 日本の細胞株開発市場規模 中国の細胞株開発市場規模 インドの細胞株開発市場規模 韓国の細胞株開発市場規模 台湾の細胞株開発市場規模 … - ヨーロッパ/中東/アフリカの細胞株開発市場規模 イギリスの細胞株開発市場規模 ドイツの細胞株開発市場規模 フランスの細胞株開発市場規模 ロシアの細胞株開発市場規模 … - その他地域の細胞株開発市場規模 ・競争状況 ・企業情報 |
The Global Cell Line Development Market size was estimated at USD 4,373.91 million in 2021 and expected to reach USD 4,986.69 million in 2022, and is projected to grow at a CAGR 14.19% to reach USD 9,698.15 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Cell Line Development to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Continuous Cell Lines, Hybridomas, Primary Cell Lines, and Recombinant Cell Lines.
Based on Source, the market was studied across Amphibian, Insect, and Mammalian.
Based on Product, the market was studied across Equipment and Media and Reagents. The Equipment is further studied across Automated Systems, Bioreactors, Biosafety Cabinets, Cell Counters and Viability Systems, Centrifuges, Filtration Systems, Incubators, Microscopes, and Storage Equipment. The Media and Reagents is further studied across Media, Reagents, and Serum. The Media is further studied across Minimum Essential Media, Reduced Serum Media, and Serum-free Media. The Reagents is further studied across Buffers and Chemicals, Cell Dissociation Reagents, Cryopreservative Reagents, and Supplements and Growth Factors. The Serum is further studied across Adult Bovine Serum and Fetal Bovine Serum.
Based on Application, the market was studied across Bioproduction, Drug Discovery, Research, Tissue Engineering & Regenerative Medicine, and Toxicity Testing. The Bioproduction is further studied across Diagnostics, Recombinant Protein Therapeutics, and Vaccine Production. The Drug Discovery is further studied across Disease Modeling, Drug Screening and Development, and Target Validation.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cell Line Development market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cell Line Development Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Line Development Market, including AGC Biologics, Aragen Bioscience, Inc., Boehringer Ingelheim International GmbH, Catalent, Inc., Corning Incorporated, EuBiologics Co.,Ltd., GE Healthcare, Genscript Biotech, Lonza Group AG, Merck KGaA, Rentschler Biopharma SE, Samsung Biologics Co., Ltd., Sartorius AG, Selexis SA, Thermo Fisher Scientific Inc., Vista Biologicals Corporation, and WuXi AppTec.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cell Line Development Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cell Line Development Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cell Line Development Market?
4. What is the competitive strategic window for opportunities in the Global Cell Line Development Market?
5. What are the technology trends and regulatory frameworks in the Global Cell Line Development Market?
6. What is the market share of the leading vendors in the Global Cell Line Development Market?
7. What modes and strategic moves are considered suitable for entering the Global Cell Line Development Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase Demand for Monoclonal Antibodies Owing to Increase Application
5.1.1.2. Innovative Technologies Coupled with Increased Participation of Research Institutes and Government Agency
5.1.1.3. Growing Rise in Vaccine Production
5.1.2. Restraints
5.1.2.1. Limited Awareness and High Cost Associated with The Product and Applications
5.1.3. Opportunities
5.1.3.1. Increasing Risk of Communicable Epidemics Diseases
5.1.3.2. Potential in Low-income Countries
5.1.4. Challenges
5.1.4.1. Developing Authentic and Stable Cell Lines
5.2. Cumulative Impact of COVID-19
6. Cell Line Development Market, by Type
6.1. Introduction
6.2. Continuous Cell Lines
6.3. Hybridomas
6.4. Primary Cell Lines
6.5. Recombinant Cell Lines
7. Cell Line Development Market, by Source
7.1. Introduction
7.2. Amphibian
7.3. Insect
7.4. Mammalian
8. Cell Line Development Market, by Product
8.1. Introduction
8.2. Equipment
8.3.1. Automated Systems
8.3.2. Bioreactors
8.3.3. Biosafety Cabinets
8.3.4. Cell Counters and Viability Systems
8.3.5. Centrifuges
8.3.6. Filtration Systems
8.3.7. Incubators
8.3.8. Microscopes
8.3.9. Storage Equipment
8.3. Media and Reagents
8.4.1. Media
8.4.2.1. Minimum Essential Media
8.4.2.2. Reduced Serum Media
8.4.2.3. Serum-free Media
8.4.2. Reagents
8.4.3.1. Buffers and Chemicals
8.4.3.2. Cell Dissociation Reagents
8.4.3.3. Cryopreservative Reagents
8.4.3.4. Supplements and Growth Factors
8.4.3. Serum
8.4.4.1. Adult Bovine Serum
8.4.4.2. Fetal Bovine Serum
9. Cell Line Development Market, by Application
9.1. Introduction
9.2. Bioproduction
9.3.1. Diagnostics
9.3.2. Recombinant Protein Therapeutics
9.3.3. Vaccine Production
9.3. Drug Discovery
9.4.1. Disease Modeling
9.4.2. Drug Screening and Development
9.4.3. Target Validation
9.4. Research
9.5. Tissue Engineering & Regenerative Medicine
9.6. Toxicity Testing
10. Americas Cell Line Development Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cell Line Development Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cell Line Development Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. AGC Biologics
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Aragen Bioscience, Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Boehringer Ingelheim International GmbH
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Catalent, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Corning Incorporated
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. EuBiologics Co.,Ltd.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. GE Healthcare
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Genscript Biotech
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Lonza Group AG
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Merck KGaA
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Rentschler Biopharma SE
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Samsung Biologics Co., Ltd.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Sartorius AG
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Selexis SA
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Thermo Fisher Scientific Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Vista Biologicals Corporation
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. WuXi AppTec
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing